A leader in the glaucoma subspecialty, Dr Cheng presented 12 months’ worth of data from his registry study assessing the efficacy of the new iTrack Advance canaloplasty device for treating a broad patient population, including primary angle-closure glaucoma.* He discussed his early clinical experience with the device, patient selection criteria and surgical pearls.
In addition to sharing his findings with conference delegates, Dr Cheng graduated from the APAO Leadership Development Program.
‘I feel privileged to have been selected by the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) for this prestigious program,’ Dr Cheng says. ‘It was certainly a proud moment to represent Australia and meet the 17 candidates from other Asia-Pacific countries.’
‘This program broadened my knowledge of effective leadership skills including communication and organisational abilities, ethics, project management and advocacy,’ he says.
Dr Cheng is already putting his learnings to good use – while at the conference, he was appointed Secretary for the APAO Gateway Committee.
‘The Gateway Project aims to reduce the prevalence of visual disability and blindness in the Asia-Pacific region. We examine the ophthalmic needs of developing countries and provide the education and infrastructure to help raise the standard of eye care,’ he says.
Dr Cheng operates at Forest Road Day Surgery and consults at the co-located Vision Eye Institute Hurstville clinic, where he is the managing partner. He is also a member of the Forest Road Day Surgery Medical Advisory Committee.
Congratulations Dr Cheng – what an amazing achievement!
*iTrack Advance has not been cleared for the reduction of IOP in adult patients with PACG.